Core Insights - Albert Anthony is a Croatian-American business author and analyst contributing to Seeking Alpha and other financial platforms, with a focus on Real Estate Investment Trusts (REITs) [1] - He has a background in business information systems and experience at Charles Schwab, which supports his analytical capabilities in equities research [1] - Anthony operates his own boutique equities research firm, Albert Anthony & Company, remotely from Texas, and is actively involved in the REIT investment space [1] Company Background - Albert Anthony & Company is a Texas-registered business that provides market commentary and research based on publicly available data [1] - The firm does not manage client funds or provide personalized financial advisory services, focusing instead on general market insights [1] Author's Qualifications - Anthony holds a B.A. in Political Science and is certified in Microsoft Fundamentals and CompTIA Project+ [1] - He is pursuing ongoing certifications in Capital Markets & Securities Analyst (CMSA) and business intelligence/data analysis through the Corporate Finance Institute [1] Media Presence - Anthony has a growing presence on YouTube, where he discusses REITs and shares insights from his investment portfolio [1] - He has participated in numerous business and innovation conferences, enhancing his visibility in the financial community [1]

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The Small Cap Core Strategy reported solid results for the quarter but did not keep pace with the sharp rally, thus lagging the benchmark. The market’s preference for lower-quality companies persisted in the quarter and contributed significantly to the benchmark’s outperformance. On the other hand, the strategy remains focused on higher-quality compa ...

Core Insights - SuperCom has secured a new electronic monitoring service provider contract in North Carolina, marking its first deployment in the state and expanding its reach to 15 U.S. states since mid-2024 [1][2][3] - The contract establishes SuperCom as the primary EM technology partner, transitioning existing GPS tracking infrastructure to its proprietary technology and software platform, following a recurring revenue model based on active daily units [2][3] - The decision by the North Carolina service provider reflects a competitive evaluation and ongoing demand for SuperCom's advanced EM solutions among regional providers [3] Company Expansion - SuperCom's entry into North Carolina is part of its U.S. expansion strategy, with 16 service provider contracts signed and 15 new states entered since mid-2024 [4] - The company emphasizes its ability to displace incumbent vendors and establish a durable presence in new geographies [4] Financial Performance - SuperCom reported a record net income of $6 million and an EBITDA margin exceeding 35% for the first nine months of 2025, indicating strong operational and financial health to support continued expansion [4]

Stock futures are lower, but well off session lows, as traders await delayed jobs data that will shape the Fed’s next move. As of 7:15am, S&P 500 futures are 0.2% lower while Nasdaq 100 contracts are -0.3% with all Mag 7 names lower premarket; European equities are little changed.Treasuries are lower, pushing 10Y yields up 0.5bps to 4.175%. The Bloomberg dollar index is at session lows. Brent crude dropped 1.6% below $60 a barrel for the first time since May and gold pulled back after five days of gains. Bi ...

Veru Inc. (NASDAQ:VERU) will release earnings results for its fourth quarter before the opening bell on Wednesday, Dec. 17.Analysts expect the Miami, Florida-based company to report quarterly loss at 39 cents per share, versus a year-ago loss of 52 cents per share, according to Benzinga Pro.On Oct. 30, Veru announced pricing of $25 million public offering of 1.4 million shares of common stock at a price of $3.00 per unit.Shares of Veru fell 1.2% to close at $2.39 on Monday.Benzinga readers can access the la ...

SHIYAN, China--(BUSINESS WIRE)--On November 19, the 2026 Overseas Commercial Vehicle Partnership Summit was held in Shiyan, Hubei Province. During the Summit, Dongfeng G Series high-end truck brand has offically launched for overseas markets. Integrating top-tier global supply chains and having undergone rigorous testing, the G Series offers outstanding durability and cost efficiency. With leading technologies benchmarking against world-class brands, it aims to provide efficient transportation solutions for ...

Key Information - Rathbones Group Plc disclosed a position in Bluefield Solar Income Fund Ltd, holding 8,572,993 shares, representing 1.44% of the relevant securities [1][3] - The position was disclosed as of December 15, 2025, with the disclosure made on December 16, 2025 [1][14] Positions of the Discloser - The disclosed interests include 8,572,993 ordinary shares of 0.01p, which accounts for 1.44% of the total relevant securities [3] Dealings - Rathbones Group Plc sold 7,200 shares of 0.01p ordinary shares at a price of 67.509p per unit [7]

With a market cap of $9.1 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells reagents, instruments, and services for research, diagnostics, and bioprocessing markets. The company operates through two segments: Protein Sciences and Diagnostics and Spatial Biology. Companies valued less than $10 billion are generally classified as “mid-cap” stocks, and Bio-Techne fits this criterion perfectly. The company’s offerings support applications ranging ...

Core Insights - Arch Biopartners Inc. has received ethics approval from the University Health Network Research Ethics Board for St. Michael's Hospital to participate in the Phase II trial of LSALT peptide aimed at preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI) [1][2] Company Overview - Arch Biopartners Inc. is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney diseases (CKD), with a pipeline targeting inflammation- and toxin-related kidney injury [17] Clinical Trial Details - The CS-AKI Phase II trial is an international, multi-center, randomized, double-blind, placebo-controlled study with a recruitment target of 240 patients, where subjects will receive either LSALT peptide (10mg IV twice daily for five days) or placebo [5] - The primary objective is to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery, as defined by KDIGO criteria [5][6] Current Status of the Trial - St. Michael's Hospital will be the ninth site activated globally and the fourth within a leading Canadian academic hospital network, with operational approvals and training underway before patient enrollment [2][4] - Other sites, including Toronto General Hospital and the University of Calgary, are actively enrolling patients, while Royal Columbian Hospital has received REB approval and is preparing for site initiation [4] Medical Context - CS-AKI is a common complication following cardiac surgery, affecting up to 30% of patients undergoing on-pump procedures, leading to serious complications and increased mortality [11][12] - There are currently no approved therapies for CS-AKI, highlighting a significant unmet medical need that LSALT peptide aims to address [12] Mechanism of Action - LSALT peptide is designed to prevent inflammation injury in the kidneys, lungs, and liver by binding to the dipeptidase-1 (DPEP1) enzyme, which plays a role in triggering organ inflammation [8] - Pre-clinical models have demonstrated LSALT's ability to prevent ischemia-reperfusion injury to the kidneys, supporting its therapeutic potential [8] Previous Research Findings - An earlier Phase II trial for acute lung inflammation showed that patients treated with LSALT peptide had significant reductions in inflammatory biomarkers, validating DPEP1 as a therapeutic target [9]

Core Viewpoint - Arch Biopartners Inc. has received ethics approval for St. Michael's Hospital to participate in a Phase II trial evaluating LSALT peptide for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI) [1][2]. Company Overview - Arch Biopartners Inc. is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney diseases (CKD) [16]. - The company is advancing an integrated program targeting inflammation- and toxin-related kidney injury, with LSALT peptide as its lead drug candidate [16]. Clinical Trial Details - The CS-AKI Phase II trial is an international, multi-center, randomized, double-blind, placebo-controlled study with a recruitment target of 240 patients [5]. - Patients will be randomized to receive either LSALT peptide (10mg IV twice daily for five days) or placebo, with the primary objective being to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery [5][6]. Research and Development - The trial aims to address a significant unmet medical need, as up to 30% of patients undergoing on-pump cardiac surgery develop CS-AKI, which can lead to serious complications and increased mortality [11]. - LSALT peptide works by binding to the dipeptidase-1 (DPEP1) enzyme, inhibiting its role in triggering organ inflammation, and has shown promise in pre-clinical models for preventing ischemia-reperfusion injury to the kidneys [8][7]. Collaboration and Site Activation - St. Michael's Hospital will be the ninth site activated globally and the fourth within a leading Canadian academic hospital network [2]. - Other active sites include Toronto General Hospital and the University of Calgary, with additional sites being evaluated in Canada and the United States [4].